Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Feb;5(2):286-91.
doi: 10.2215/CJN.05420709. Epub 2009 Nov 12.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Rodrigo B Oliveira  1 , Ana L E Cancela, Fabiana G Graciolli, Luciene M Dos Reis, Sérgio A Draibe, Lilian Cuppari, Aluizio B Carvalho, Vanda Jorgetti, Maria E Canziani, Rosa M A Moysés
Affiliations
Randomized Controlled Trial

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Rodrigo B Oliveira et al. Clin J Am Soc Nephrol. 2010 Feb.

Abstract

Background and objectives: Levels of parathyroid hormone (PTH) and the phosphaturic hormone FGF23, a fibroblast growth factor (FGF) family member, increase early in chronic kidney disease (CKD) before the occurrence of hyperphosphatemia. This short-term 6-wk dose titration study evaluated the effect of two phosphate binders on PTH and FGF23 levels in patients with CKD stages 3 to 4.

Design, setting, participants, and measurements: Patients were randomized to receive over a 6-wk period either calcium acetate (n = 19) or sevelamer hydrochloride (n = 21).

Results: At baseline, patients presented with elevated fractional excretion of phosphate, serum PTH, and FGF23. During treatment with both phosphate binders there was a progressive decline in serum PTH and urinary phosphate, but no change in serum calcium or serum phosphate. Significant changes were observed for FGF23 only in sevelamer-treated patients.

Conclusions: This study confirms the positive effects of early prescription of phosphate binders on PTH control. Prospective and long-term studies are necessary to confirm the effects of sevelamer on serum FGF23 and the benefits of this decrease on outcomes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Absolutes changes in the levels of serum calcium (Ca), serum phosphate (P), urinary phosphate (uP), fractional excretion of phosphate (FeP), serum PTH, and serum FGF23 in patients treated with sevelamer hydrochloride (○) or calcium acetate (■) over a 6-wk period followed by a 2-wk washout period. Statistical comparisons within and between treatment groups are shown. Data are expressed as mean ± SD, except for FGF23 and PTH, which are expressed as median (25th to 75th percentile interval).
Figure 2.
Figure 2.
Percentage change in serum FGF23 and PTH levels in patients treated with sevelamer hydrochloride (□) or calcium acetate (■) over a 6-wk period. Statistical comparisons within and between treatment groups are shown. Data are expressed as mean ± SD.
See this image and copyright information in PMC

References

    1. Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, Carvalho AB, Neto EM, Canziani ME: The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 21: 2464–2471, 2006 - PubMed
    1. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520–528, 2005 - PubMed
    1. Vassalotti JA, Uribarri J, Chen SC, Li S, Wang C, Collins AJ, Calvo MS, Whaley-Connell AT, McCullough PA, Norris KC: Kidney Early Evaluation Program Investigators: Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 51 [Suppl 2]: S56–S68, 2008 - PubMed
    1. Schiavi SC: Fibroblast growth factor 23: The making of a hormone. Kidney Int 69: 425–427, 2006 - PubMed
    1. Fukumoto S, Yamashita T: FGF23 is a hormone-regulating phosphate metabolism—Unique biological characteristics of FGF23. Bone 40: 1190–1195, 2007 - PubMed

Publication types

MeSH terms